Aveo

AVEO NASDAQ
0.6999
-0.0111
-1.56%
After Hours: 0.6990 -0.0009 -0.13% 17:13 06/14 EDT
Open
0.7200
Prev Close
0.7110
High
0.7400
Low
0.6950
Volume
1.45M
Avg Vol (3M)
6.68M
52 Week High
3.590
52 Week Low
0.4906
% Turnover
0.90%
Market Cap
112.50M
1D
5D
1M
3M
1Y
5Y

Company Profile

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
MORE >

Recently

Name
Price
%Change